Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.

Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.

Abstract: This invention discloses a pocket door. The pocket door is capable of pivoting on hinges between a fame that holds the pocket door and allows it to slide in and out of a pocket to open and close a passageway. More specifically, the pocket door is hinged to the moving frame and also includes a two-part panel, where each panel is separated from an adjacent panel by a hinge that is capable of allowing the panels to move between flush engagement wherein the two panel lie in the same plane and a position where the panels are no longer lying in the same plane.

Abstract: This invention discloses a pocket door. The pocket door is capable of pivoting on hinges between a frame that holds the pocket door and allows it to slide in and out of a pocket to open and close a passageway. More specifically, the pocket door is hinged to the moving frame and also includes a two-part panel, where each panel is separated from an adjacent panel by a hinge that is capable of allowing the panels to move between flush engagement where the two panels lie in the same plane and a position where the panels are no longer lying in the same plane.

Abstract: A driveline assembly includes a shaft that is rotatably supported on a bearing assembly within a drive axle. The shaft has a first mount portion with a threaded exterior surface and a second mount portion with a splined exterior surface. A retaining ring is threaded onto the first mount portion to engage and retain the bearing assembly at a proper location. A yoke member with a splined inner bored is mounted on the shaft in engagement with the splined exterior surface. The yoke member can easily be connected and disconnected from the shaft without having to remove the retaining ring. The yoke member also includes a quick disconnect device that simplifies removal and re-assembly of the yoke member from the shaft.

Abstract: A driveline assembly includes a shaft that is rotatably supported on a bearing assembly within a drive axle. The shaft has a first mount portion with a threaded exterior surface and a second mount portion with a splined exterior surface. A retaining ring is threaded onto the first mount portion to engage and retain the bearing assembly at a proper location. A yoke member with a splined inner bored is mounted on the shaft in engagement with the splined exterior surface. The yoke member can easily be connected and disconnected from the shaft without having to remove the retaining ring. The yoke member also includes a quick disconnect device that simplifies removal and re-assembly of the yoke member from the shaft.